Immune tolerance mediated by recombinant proteolipid protein prevents experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 79, Issue 1, 1997, Pages 1-11

  Elliott, Eileen A ^a   Cofiell, Roxanne ^a   Wilkins, James A ^a   Raine, Cedric S ^b   Matis, Louis A ^a   Mueller, John P ^a  

^a Depts Immunobiol and Proc Devmt   (United States)

^b Neurol Neurosci Albert E   (United States)

Author keywords

Apoptosis; Autoimmunity; Experimental autoimmune encephalomyelitis; Immune tolerance; Multiple sclerosis; Proteolipid protein; T cells

Indexed keywords

AUTOANTIGEN; EPITOPE; OVALBUMIN; PROTEOLIPID PROTEIN; RECOMBINANT PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATION; FEMALE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED STRAINS; MYELIN PROTEOLIPID PROTEIN; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 0030696797     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00093-3     Document Type: Article

References (60)

1. Bitar C.M., Whitacre C.C. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. Cell. Immunol. 112:1988;364-370.
2. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D., Veromenaa T., Waisman A., Gaur A., Conlon P., Ling N., Fairchild P.J., Wraith D.C., O'Garra A., Fathman C.G., Steinman L. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:1996;343-346.
3. Chou Y.K., Bourdette D.N., Offner H., Whitham R., Wang R.-Y., Hashim G.A., Vandenbark A.A. Frequency of T-cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J. Neuroimmunol. 38:1992;105-114.
4. Clayton J.P., Gammon G.M., Ando D.G., Kono D.H., Hood L., Sercarz E.E. Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T-cell determinant of myelin basic protein. J. Exp. Med. 169:1989;1681-1691.
5. Correale J., McMillan M., McCarthy K., Le T., Weiner L.P. Isolation and characterization of autoreactive proteolipid protein T-cell clones from multiple sclerosis patients. Neurology. 45:1995;1370-1378.
6. Critchfield J.M., Racke M.K., Zuniga-Pflucker J.C., Cannella B., Raine C.S., Goverman J., Lenardo M.J. T-cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science. 263:1994;1139-1143.
7. Cross A.H., Tuohy V.K., Raine C.S. Development of reactivity of new myelin antigens during chronic relapsing autoimmune demyelination. Cell. Immunol. 146:1993;261-269.
8. Degermann S., Pria E., Adorini L. Soluble protein but not peptide administration diverts the immune response of a clonal CD4+ T-cell population to the T helper 2 cell pathway. J. Immunol. 157:1996;3260-3269.
9. Endoh M., Tabira T., Kunishita T., Sakai K., Yamamura T., Taketomi T. DM-20, a proteolipid apoprotein, is an encephalitogen of acute and relapsing autoimmune encephalomyelitis in mice. J. Immunol. 137:1986;3832-3835.
10. Elliott E.A., McFarland H.I., Nye S.H., Cofiell R., Wilson T.M., Wilkins J.A., Squinto S.P., Matis L.A., Mueller J.P. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J. Clin. Invest. 98:1996;1602-1612.
11. H2 immunity in neonatal mice. Science. 271:1996;1728-1730.
12. Gaur A., Wiers B., Liu A., Rothbard J., Fathman C.G. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Nature. 258:1992;1491-1494.
13. Greer J.M., Kuchroo V.K., Sobel R.A., Lees M.B. Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice. J. Immunol. 149:1992;783-788.
14. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 77:1989;51-59.
15. Kearney E.R., Pape K.A., Loh D.Y., Jenkins M.K. Visualization of peptide-specific T-cell immunity and peripheral tolerance induction in vivo. Immunity. 1:1994;327-339.
16. Kennedy M.K., Tan L.-J., Dal Canto M.C., Tuohy V.K., Lu Z., Trotter J.L., Miller S.D. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J. Immunol. 144:1990;909-915.
17. Kronquist K.E., Crandall B.F., Macklin W.B., Campagnoni A.T. Expression of myelin proteins in the developing human spinal cord: Cloning and sequencing of human proteolipid protein cDNA. J. Neurosci. Res. 18:1987;395-440.
18. Kuchroo V.K., Collins M., Al-Sabbagh A., Sobel R.A., Whitters M.J., Zamvil S.S., Dorf M.E., Hafler D.A., Seidman J.G., Weiner H.L., Rimm I.J. T-cell receptor (TCR) usage determines disease susceptibility in experimental autoimmune encephalomyelitis: Studies with TCR Vβ 8.2 transgenic mice. J. Exp. Med. 179:1994;1659-1664.
19. Kuchroo V.K., Sobel R.A., Laning L.C., Greenfield E., Martin C., Dorf M.E., Lees M.B. Experimental allergic encephalomyelitis mediated by cloned T-cells specific for a synthetic peptide of myelin proteolipid protein: Fine specificity and TCR Vβ usage. J. Immunol. 148:1992;3776-3782.
20. Lehman P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358:1992;155-157.
21. Liblau R.S., Tisch R., Shokat K., Yang X.-D., Dumont N., Goodnow C.C., McDevitt H.O. Intravenous injection of soluble antigen induces thymic and peripheral T-cell apoptosis. Proc. Natl. Acad. Sci. USA. 93:1996;3031-3036.
22. Markovic-Plese S., Fukaura H., Zhang J., Al-Sabbagh A., Scottwood S., Sette A., Kuchroo V.K., Hafler D.A. T-cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J. Immunol. 155:1995;982-992.
23. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating disease. Annu. Rev. Immunol. 10:1992;153-187.
24. McCarron R.M., Fallis R.J., McFarlin D.E. Alterations in T-cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J. Neuroimmunol. 29:1990;73-79.
25. McRae B.L., Kennedy M.K., Tan L.-J., Dal Canto M.C., Picha K.S., Miller S.D. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J. Neuroimmunol. 38:1992;229-240.
26. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182:1995;75-85.
27. Nicholson L.B., Greer J.M., Sobel R.A., Lees M.B., Kuchroo V.K. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity. 3:1995;397-405.
28. Nye S.H., Pelfrey C.M., Burkwitt J., Voskuhl R.R., Lenardo M.J., Mueller J.P. Purification of immunologically active 21.5 kDa isoform of myelin basic protein. Mol. Immunol. 32:1995;1131-1141.
29. Ohnishi T., Yamamura T., Inobe J., Kondo T., Kunishita T., Tabira T. Analysis of proteolipid protein (PLP)-specific T-cells in multiple sclerosis: Identification of PLP 95-106 as an HLA-DR2, w15-associated determinant. Int. Immunol. 7:1995;1771-1778.
30. Olsson T., Zhi W.W., Hojeberg B., Kostulas V., Jiang Y.P., Anderson G., Ekre H.P., Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J. Clin. Invest. 86:1990;981-985.
31. + T-cells from multiple sclerosis patients. J. Neuroimmunol. 46:1993;33-42.
32. + T-cells from multiple sclerosis patients. J. Neuroimmunol. 53:1994;153-161.
33. Perry L.A., Barzaga-Gilbert E., Trotter J.L. T-cell sensitization to proteolipid protein in myelin basic protein-induced relapsing experimental allergic encephalomyelitis. J. Neuroimmunol. 33:1991;7-15.
34. Racke M.K., Critchfield J.M., Quigley L., Cannella B., Raine C.S., McFarland H.F., Lenardo M.J. Intravenous antigen administration as a therapy for autoimmune demyelinating disease. Ann. Neurol. 39:1996;46-56.
35. Raine C.S. Biology of disease. The analysis of autoimmune demyelination: Its impact upon multiple sclerosis. Lab. Invest. 50:1984;608-635.
36. Samson M.F., Smilek D.E. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J. Immunol. 155:1995;2737-2746.
37. Satoh J., Sakai K., Endoh M., Koike F., Kunishita T., Namikawa T., Yamamura T., Tabira T. Experimental allergic encehalomyelitis mediated by murine encephalitogenic T-cell lines specific for myelin proteolipid apoprotein. J. Immunol. 138:1987;179-184.
38. Sharma S.D., Nag B., Su X.-M., Green D., Spack E., Clark B.R., Sriram S. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc. Natl. Acad. Sci. USA. 88:1991;11465-11469.
39. Singer G.G., Abbas A.K. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T-cell receptor transgenic mice. Immunity. 1:1994;365-371.
40. Sobel R.A., Kuchroo V.K. The immunopathology of acute experimental allergic encephalomyelitis induced with myelin proteolipid protein. T-cell receptors in inflammatory lesions. J. Immunol. 149:1992;1444-1451.
41. Sobel R.A., Greer J.M., Kuchroo V.K. Minireview: Autoimmune responses to myelin proteolipid protein. Neurochem. Res. 19:1994;915-921.
42. Studier F.W., Rosenberg A.H., Dunn J.J., Dubendorff J.W. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 185:1990;60-89.
43. Sun J.-B., Olsson T., Wang W.-Z., Xiao B.-G., Kostulas V., Fredrikson S., Ekre H.-P., Link H. Autoreactive T- and B-cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur. J. Immunol. 21:1991;1461-1468.
44. Tan L., Kennedy M.K., Dal Canto M.C., Miller S.D. Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance. J. Immunol. 147:1990;1797-1802.
45. Trotter J.L., Clark H.B., Collins K.G., Wegenscheide C.L., Scarpellini J.D. Myelin proteolipid protein induces demyelinating disease in mice. J. Neurol. Sci. 79:1987;173-188.
46. Trotter J.L., Hickey W.F., van der Veen R.C., Sulze L. Peripheral blood mononuclear cells from multiple sclerosis patients recognize myelin proteolipid protein and selected peptides. J. Neuroimmunol. 33:1991;555-562.
47. Tuohy V.K. Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: A review. Neurochem. Res. 19:1994;935-944.
48. Tuohy V.K., Fritz R.B., Ben-Nun A. Self-determinant in autoimmune demyelinating disease: Changes in T-cell response specificity. Curr. Opin. Immunol. 6:1994;887-891.
49. Tuohy V.K., Lu Z., Sobel R.A., Laursen R.A., Lees M.B. A synthetic peptide from myelin proteolipid protein induces experimental allergic encehalomyelitis. J. Immunol. 141:1988;1126-1130.
50. Tuohy V.K., Lu Z., Sobel R.A., Laursen R.A., Lees M.B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142:1989;1523-1527.
51. Tuohy V.K., Sobel R.A., Lees M.B. Myelin proteolipid protein-induced experimental allegic encephalomyelitis. J. Immunol. 140:1988;1868-1873.
52. Tuohy V.K., Sobel R.A., Lu Z., Laursen R.A., Lees M.B. Myelin proteolipid protein: Minimum sequence requirements of active induction of autoimmune encephalomyelitis in SWR/J and SJL/J mice. J. Neuroimmunol. 39:1992;67-74.
53. Van der Veen R.C., Trotter J.L., Clark H.B., Kapp J.A. The adoptive transfer of chronic relapsing experimental allergic encephalomyelitis with lymph node cells sensitized to myelin proteolipid protein. J. Neuroimmunol. 21:1989;183-191.
54. Van der Veen R.C., Trotter J.L., Hickey W.F., Kapp J.A. The development and characterization of encephalitogenic cloned T-cells specific for myelin proteolipid protein. J. Neuroimmunol. 26:1990;139-145.
55. Van der Veen R.C., Trotter J.L., Kapp J.A. Immune processing of proteolipid protein by subsets of antigen presenting spleen cell. J. Neuroimmunol. 38:1992;139-146.
56. Weimbs T., Stoffel W. Proteolipid protein (PLP) of CNS myelin: Positions of free, disulfide-bonded, and fatty acid thioester-linked cysteine residues and implications for the membrane topology of PLP. Biochemistry. 31:1992;12289-12296.
57. Whitman, R.H., Bourdette, D.N., Hashim, G.A., Herndon, R.M., Ilg., R.C., Vandenbark, A.A., Offner, H., 1991a. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 146, 101-107.
58. 1 mice. J. Immunol. 147:1991;3803-3808.
59. Yu M., Johnson M.J., Tuohy V.K. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 183:1996;1777-1788.
60. Zhang J.S., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., Hafler D.A. Increased frequency of interleukin 2-responsive T-cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179:1994;973-984.